2. MAPK/ERK Pathway
  3. MAP3K
  4. CS17919

CS17919 is a potent, selective and orally active ASK1 inhibitor with an IC50 of 22.52 nM. CS17919 shows anti-inflammatory and antifibrotic effects. CS17919 can be used for the study of metabolic-related kidney and liver diseases.

For research use only. We do not sell to patients.

CS17919 Chemical Structure

CS17919 Chemical Structure

CAS No. : 2379346-41-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

CS17919 Related Antibodies

Top Publications Citing Use of Products

View All MAP3K Isoform Specific Products:

View All Isoforms
MAP3K7/TAK1 MAP3K8 ASK2 MAP3K5/ASK1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CS17919 is a potent, selective and orally active ASK1 inhibitor with an IC50 of 22.52 nM. CS17919 shows anti-inflammatory and antifibrotic effects. CS17919 can be used for the study of metabolic-related kidney and liver diseases[1].

IC50 & Target[1]

ASK1

22.52 nM (IC50)

In Vitro

CS17919 (0.32-10 μM; 72 h) provids potent protection in Palmitic acid-treated LO2 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CS17919 Related Antibodies

Apoptosis Analysis[1]

Cell Line: L02 cells stimulated with 50 μM Palmitic acid (HY-N0830)
Concentration: 0.32 μM, 0.63 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM
Incubation Time: 72 h
Result: Significantly prevented apoptosis at all doses.
In Vivo

CS17919 (10-60 mg/kg; po; twice daily; for 11 days) improves kidney injury and fibrosis in the UUO model[1].
CS17919 (50 mg/kg; po; twice daily; for 70 days) alleviates glomerular sclerosis in a DKD model[1].
CS17919 (20 mg/kg; po; twice daily; for 4 weeks) ameliorates liver inflammation and fibrosis in a NASH model[1].
Pharmacokinetic parameters of CS17919 in C57BL/6J following oral administration[1].
1.19

Parameters 20 mg/kg. p.o. 50 mg/kg. p.o.
AUC0–∞ (h·ng/mL) 23 113 ± 5898.47 58 795 ± 23 199.32
AUC0–t (h·ng/mL) 23 078 ± 5892.78 57 239 ± 20 606.29
Cmax (ng/mL) 4039 ± 646.90 5741 ± 1835
MRT0–∞ (h) 3.96 ± 0.91 6.43 ± 1.44
T1/2 (h) 2.20 ± 0.74 3.50 ± 1.86
Tmax (h) 1.50 ± 0.87 2.00 ± 0

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C57BL/6J mice (6-8 weeks old) bearing unilateral ureteral obstruction model (UUO)[1]
Dosage: 10 mg/kg, 60 mg/kg (0.2% CMC-Na + 0.1% Tween-80)
Administration: po; twice daily; for 11 days
Result: Preserved kidney function and showed a non-significant tendency to alleviate kidney fibrosis.
Animal Model: Male neonatal mice bearing chronic kidney disease (CKD)[1]
Dosage: 50 mg/kg
Administration: po; twice daily; for 70 days
Result: Significantly improved serum creatinine and glomerular sclerosis.
Animal Model: Male C57BL/6J mice (6-8 weeks) bearing non-alcoholic steatohepatitis (NASH)[1]
Dosage: 20 mg/kg
Administration: po; twice daily; for 4 weeks
Result: Significantly improved liver inflammation and substantially reduced liver fibrosis.
Molecular Weight

476.43

Formula

C22H20F4N6O2
CAS No.
SMILES

CC1=C(C=C(C(F)=C1)C(NC2=NC(C3=NN=CN3[C@@H](C(F)(F)F)C)=CC=C2)=O)NC(C4CC4)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CS17919 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CS179192379346-41-3CS 17919CS-17919MAP3KMAP kinase kinase kinase, MEKK, MAPKKKASK1 inhibitororally activeanti-inflammatory and antifibrotic effectsmetabolic-related kidney and liver diseasesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CS17919
Cat. No.:
HY-163752
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.